Oncology · Hepatocellular CarcinomaOtherclinicalmid-term

MAGED4 promotes HCC progression via JAK2/STAT3 pathway activation

Importance8/ 10

ActionInvestigate

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/20/2026, 12:32:23 AM

Assessment confidence: 83% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The upregulation of MAGED4 in HCC and its role in tumor progression via the JAK2/STAT3 pathway presents a significant opportunity for new therapeutic strategies. This could reshape treatment paradigms and competitive dynamics in the oncology space, particularly for HCC. Regulatory context from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) supports the near-term read. Assessment grounded in 5 ranked evidence items (4 high-relevance).

Strategic Assessment

The strongest clinical anchor is A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma (ClinicalTrials.gov), sub-indication match (liver cancer). Developing MAGED4 inhibitors could lead to a new class of therapies for HCC, potentially capturing significant market share and enhancing competitive positioning against existing treatments.

Competitive Pressure

The most relevant competitive pressure comes from The findings suggest that MAGED4 could be a potential therapeutic target in HCC, impacting current treatment strategies and competitive positioning..

Regulatory Outlook

Regulatory risk is concentrated around If MAGED4-targeted therapies are developed, they will require regulatory approval, which could involve navigating complex clinical trial requirements and safety assessments..

Key Risks

Elevated medium regulatory exposure for MAGED4 could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Signal severity is high — leadership review is warranted.

Key Opportunities

Developing MAGED4 inhibitors could lead to a new class of therapies for HCC, potentially capturing significant market share and enhancing competitive positioning against existing treatments.
Upside for MAGED4 may improve if A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Exploring MAGED4 inhibitors or related therapies as potential new treatment options for HCC.

What Would Change This Assessment

This becomes more urgent if Monitor developments in MAGED4-targeted therapies and clinical trials focusing on HCC.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Sunscreen: How to Help Protect Your Skin from the Sun
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
ClinicalTrials.govmedium relevance
Sub-indication match (liver cancer)
FDA document
View source
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

MAGED4 promotes hepatocellular carcinoma progression via activation of JAK2/STAT3 pathway by stabilizing TRIM21.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (maged4)
FDA document
View source
Centromere protein I promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR-CDK2 cascade.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (hepatocellular carcinoma hcc )
FDA document
View source
Dual-ligand-modified cantharidin nanoparticles for the treatment of hepatocellular carcinoma via the inhibition of Ephb4.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (hepatocellular carcinoma hcc )
FDA document
View source
Patients with Favorable Prognosis among Those Selected for Liver Resection for Intermediate-Stage Hepatocellular Carcinoma.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (hepatocellular carcinoma hcc )
FDA document
View source
Thyroid cancer-derived exosomal SPP1 promotes tumor progression by driving macrophage M2 polarization through the CD44/JAK2/STAT3 signaling pathway.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Intratumor Lactobacillus drives ferroptosis resistance via D-lactate-STAT3 K631 lactylation in esophageal squamous cell carcinoma.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

MAGED4
Hepatocellular Carcinoma (HCC)

Commercial impact

high

Developing MAGED4 inhibitors could lead to a new class of therapies for HCC, potentially capturing significant market share and enhancing competitive positioning against existing treatments.

Regulatory impact

medium

If MAGED4-targeted therapies are developed, they will require regulatory approval, which could involve navigating complex clinical trial requirements and safety assessments.

What to watch

Monitor developments in MAGED4-targeted therapies and clinical trials focusing on HCC.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.